Last reviewed · How we verify
ICOTINIB
At a glance
| Generic name | ICOTINIB |
|---|---|
| Sponsor | Zhejiang Beta Pharma Inc. |
| Target | Epidermal growth factor receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
Common side effects
Key clinical trials
- Therapy for Advanced NSCLC With EGFR 19delins Mutation (EARLY_PHASE1)
- Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation (PHASE2)
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (PHASE2,PHASE3)
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations (PHASE3)
- Icotinib for Completed Resected IB NSCLC With EGFR Mutation (PHASE2)
- Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (PHASE3)
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer (PHASE2)
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICOTINIB CI brief — competitive landscape report
- ICOTINIB updates RSS · CI watch RSS
- Zhejiang Beta Pharma Inc. portfolio CI